公司資料
Edwards Lifesciences 股價、新聞與催化劑
- 股票代碼:
- EW
- 交易所:
- NYSE
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
88.25 USD (-1.15%)
收盤價
最後更新: 2026年9月17日
50.5B USD
市值
股價為何變動
截至 2026年9月17日，EW 下跌 1.15%，收於 $88.25。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
業務概覽
Edwards Lifesciences is a medical technology company best known for transcatheter heart valve therapies and critical care monitoring. The business is centered on structural heart innovation and procedure adoption.
所在地與產業分類
Headquartered in the United States and listed on NYSE, Edwards is a global medtech company with strong exposure to cardiovascular procedures. It sits outside biotech and closer to high-end medical devices.
商業模式特徵
The company generates revenue through transcatheter valve systems, monitoring technologies, and related procedure-based products. Investors focus on procedure growth, product expansion, and how well the company can keep widening adoption in structural heart care.
生技產業定位
Edwards is not biotech proper, but it occupies a premium position in healthcare innovation. It tends to move on device adoption and clinical uptake rather than on drug approvals or pipeline readouts.
未來催化劑
- Edwards Lifesciences is likely to be driven by TAVR demand, EVOQUE adoption in tricuspid therapy, and continued SAPIEN franchise strength. The key question is whether the update shows enough repeatable demand to look like a durable revenue driver rather than a one-quarter bump. If adoption broadens, sentiment can improve faster than the reported numbers alone would suggest.
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
- 01
- 02
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。